Nutrients

Probiotic NVP-1704’s effects on mental health and sleep in healthy adults over 8 weeks

Updated

Abstract

Probiotic NVP-1704 led to significant reductions in depressive symptoms for 156 participants over eight weeks.

  • The NVP-1704 group showed a reduction in depressive symptoms at both four and eight weeks compared to the placebo group.
  • Anxiety symptoms were significantly lower in the NVP-1704 group at four weeks.
  • Participants receiving NVP-1704 reported improved sleep quality.
  • Blood tests indicated a decrease in serum interleukin-6 levels following NVP-1704 treatment.
  • NVP-1704 altered composition, with increases in certain beneficial bacteria.

Simplified

Key numbers

8.02
Decrease in Depression Symptoms
BDI-II score change at eight weeks for NVP-1704 group.
5.30
Decrease in Anxiety Symptoms
BAI score change at eight weeks for NVP-1704 group.
21 of 63
Clinically Meaningful Improvement in Sleep Quality
Rate of improvement in PSQI scores after eight weeks for NVP-1704 group.

Full Text

What this is

  • This trial evaluated the effects of probiotic NVP-1704 on mental health and sleep in healthy adults.
  • 156 participants with subclinical symptoms of depression, anxiety, and insomnia were randomly assigned to receive NVP-1704 or a placebo for eight weeks.
  • Outcomes included mood, sleep quality, and blood biomarkers, with assessments at baseline, four weeks, and eight weeks.

Essence

  • NVP-1704 significantly reduced depressive and anxiety symptoms and improved sleep quality in healthy adults. It also decreased serum interleukin-6 levels, indicating potential anti-inflammatory effects.

Key takeaways

  • NVP-1704 led to a greater reduction in depressive symptoms compared to placebo, with BDI-II scores decreasing by −8.02 in the NVP-1704 group vs. −5.39 in the placebo group at eight weeks.
  • Anxiety symptoms decreased more in the NVP-1704 group, with BAI scores showing a reduction of −5.30 vs. −2.93 in the placebo group at the final visit.
  • NVP-1704 improved sleep quality, with significant reductions in PSQI and ISI scores after eight weeks, achieving clinically meaningful improvements in 33.3% of participants vs. 15.3% in the placebo group.

Caveats

  • The study's per-protocol analysis may overestimate treatment efficacy and underestimate adverse reactions due to dropout rates exceeding 20%.
  • The absence of pre-treatment composition analysis limits understanding of baseline differences and treatment effects.
  • The study's retrospective registration may not align with international standards, potentially affecting its credibility.

Definitions

  • probiotics: Live beneficial microorganisms that may improve health by restoring gut microbiome balance.
  • gut microbiota: A community of microorganisms in the gastrointestinal tract that influences health and disease.

Simplified

Funding

Competing interests

Jang S.W. and Han S.-W. are employees of Navipharm Inc., which provided study products. Other authors declare that there are no potential conflicts of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free